Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aggressive Therapy Clear all
Completed Phase 1 Interventional

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

NCT03036904
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions
Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Group-Based Behavioral Therapy Combined With Stimulant Medication for Treating Children With Attention Deficit Hyperactivity Disorder and Impaired Mood

NCT00632619
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Group-based behavior therapy, Stimulant medication therapy, Community-based psychosocial treatment
Behavioral · Drug
Lead sponsor
Florida International University
Other
Eligibility
7 Years to 11 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

NCT05665530
View directory record Official record
Conditions
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
Interventions
PRT2527, Zanubrutinib, Venetoclax
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Duarte, California • Bethesda, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma

NCT00016094
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions
bevacizumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Sep 12, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

NCT07704918
View directory record Official record
Conditions
Melanoma
Interventions
Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Phase 4 Interventional

Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings

NCT02078596
View directory record Official record
Conditions
Irritable Aggression
Interventions
Divalproex
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
7 Years to 11 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 12, 2026, 9:03 AM EDT
Active, not recruiting Phase 2 Interventional

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

NCT00929214
View directory record Official record
Conditions
Breast Cancer
Interventions
Standard Therapy, Local Therapy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 12, 2026, 9:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia

NCT01486784
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Birinapant
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 12, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

Regulating Together for Intellectual Disability and Autism: A Group Behavioral Therapy for for Emotion Dysregulation

NCT07624448
View directory record Official record
Conditions
Autism, Intellectual Disabilities With Other Behavioral Symptoms, Intellectual Disability
Interventions
Regulating Together group therapy
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 12, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional Results available

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

NCT02992132
View directory record Official record
Conditions
Agitation and Aggression in Alzheimer's Disease
Interventions
Pimavanserin 34 mg, Pimavanserin 20 mg, Placebo
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
33
States / cities
Costa Mesa, California • Fresno, California • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Evaluating the Feasibility of RESCUE: An Adjunctive HAI-Based Intervention for Veterans With PTSD

NCT03504722
View directory record Official record
Conditions
PTSD
Interventions
RESCUE, Prolonged Exposure
Behavioral
Lead sponsor
Charleston Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01364662
View directory record Official record
Conditions
Impulsive Aggression Comorbid With ADHD
Interventions
SPN-810, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Dothan, Alabama • Los Angeles, California • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression

NCT00621751
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Carbamazepine, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
16 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

NCT01103440
View directory record Official record
Conditions
Stable Angina
Interventions
Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)

NCT03230175
View directory record Official record
Conditions
Non-healing Wound, Non-healing Diabetic Foot Ulcer, Diabetic Foot Infection
Interventions
TTAX01, Surgical resection and debridement, Systemic antibiotics, Off-loading
Biological · Procedure · Drug + 1 more
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Phoenix, Arizona • Sylmar, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Phase 3 Interventional

Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation

NCT00007657
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Intensive medical therapy, Percutaneous Coronary Intervention (PCI) plus intensive medical therapy
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
3,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
34
States / cities
Scottsdale, Arizona • No. Little Rock, Arkansas • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2009 · Synced Sep 12, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Trials to Reduce the Risk of Antimicrobial Resistance

NCT01570192
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease

NCT01924312
View directory record Official record
Conditions
Cerebrovascular Disease, Mild Cognitive Impairment
Interventions
Heart Health Intervention
Behavioral
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
55 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 12, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Treatment of Chronic Anger and Aggression Following Military-Related Betrayal

NCT06609330
View directory record Official record
Conditions
Anger Problems, Aggression
Interventions
Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Fort Cavazos, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

NCT01528709
View directory record Official record
Conditions
Saphenous Vein Graft Disease
Interventions
Atorvastatin 80 mg daily, Atorvastatin 10 mg daily
Drug
Lead sponsor
Boca Raton Regional Hospital
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Breaking the Cycle IV: Military PTSD (MPTSD) Treatment Study

NCT01228539
View directory record Official record
Conditions
PTSD, Anger, Aggression
Interventions
TARGET (Trauma Affect Regulation), Prolonged Exposure
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced Sep 12, 2026, 9:03 AM EDT
Recruiting Phase 2 Interventional

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

NCT03121001
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ATG, fludarabine, cyclophosphamide, Total body irradiation, Stem cell infusion, Sirolimus, mycophenolate mofetil
Drug · Radiation · Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
16 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 12, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

NCT03483103
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Interventions
lisocabtagene maraleucel
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
59
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 12, 2026, 9:03 AM EDT
Withdrawn Not applicable Interventional

Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford

NCT05416554
View directory record Official record
Conditions
Non Hodgkin Lymphoma
Interventions
Neuropsychological testing
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 12, 2026, 9:03 AM EDT